NCE-1 Intelligence & Market Opportunity

Scemblix

Asciminib

Anticancer

Oral Tablet

Approval Date

29-Oct-21

NCE-1 Date

29-Oct-25

NCE Date

29-Oct-26

Commercial snapshot

Market performance & projections

Revenue ($M)

1285

CAGR (%)

0.2697

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

1925

2027

2483

2028

2952

2029

3340

2030

3674

2031

4010

2032

4327

Molecule profile

Details & specifications

Molecule

Asciminib

Innovator

NOVARTIS PHARMACEUTICALS CORPORATION

Dosage Form

Oral Tablet

Strength

EQ 40 mg base, EQ 100 mg base, EQ 20 mg base

Therapeutic Category

Anticancer

Usage

To treat Philadelphia chromosome-positive chronic myeloid leukemia with disease that meets certain criteria

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.